Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

 Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

Takeda Exercises its Exclusive Option to Acquire PvP Biologics for ~$330M

Shots:

  • Takeda acquires PvP Biologics following the P-I proof-of-mechanism study of TAK-062 (Kuma062) to treat uncontrolled celiac disease. Takeda exercises its option to acquire by paying ~$330M as development & regulatory milestone including $35M up front
  • In 2017, the companies collaborated to develop novel therapies for celiac disease, under which Takeda got exclusive option to acquire PvP following receipt of a pre-defined development plan
  • TAK-062 is designed to digest gluten before they exit the stomach, thus eliminating the symptoms and intestinal damage caused by celiac disease. Takeda is planning to initiate P-IIb study assessing TAK-062 in patients with the uncontrolled disease, maintaining a gluten-free diet

Click here ­to­ read full press release/ article | Ref: Takeda | Image: China Daily

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post